Figure 4.

Robustness of HER2DX: evaluation of non-tumor component and different starting RNA quantities. (A) Overview of the spiking experiment designed; (B) boxplot representing the percentiles for the three HER2DX scores (i.e. relapse risk score, pCR likelihood score, and ERBB2 score) after diluting tumor-derived RNA in stroma-derived RNA; (C) overview of the experiment design to evaluate the effect of starting from different RNA quantities; (D) boxplot representing the percentiles for the three HER2DX scores (relapse risk score, pCR likelihood score, and ERBB2 score) after starting from different quantities of RNA.

Ctl, control; FFPE, formalin-fixed paraffin-embedded; mRNA, messenger RNA; pCR, pathological complete response.